Le Lézard
Classified in: Science and technology
Subject: v

Critical Control Declares Dividend

CALGARY, Alberta, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. ("Critical Control" or the "Corporation") (TSX:CCZ); (TSX:CCZ.PR.A) announces that the directors of the Corporation declared a quarterly cash dividend on its series A preferred shares of $0.04 per share, payable on or about December 31, 2017 to shareholders of record at the close of business on December 15, 2017.  This dividend represents a cash dividend of $0.16 per series A preferred share on an annualized basis.

Critical Control expects this dividend to be designated as an "eligible dividend" for Canadian income tax purposes.

About Critical Control

Critical Control provides solutions for the collection, control and analysis of measurement and operational data related to oil and gas wells across North America.  We provide services to capture the data, cloud-based software to visualize and manage it and the business intelligence to make quicker and more informed operational decisions.

For further information

Alykhan Mamdani
President & CEO
Tel (403) 705-7500

These press releases may also interest you

at 20:45
Global HR executive search, consulting and outplacement firm Frederickson Partners (www.fredericksonpartners.com), formerly Frederickson Pribula Li, today announced record growth, expanded markets, and organizational changes. In 2017, the...

at 20:41
Cision today announced the pricing of an underwritten public offering of 5,750,000 ordinary shares by certain selling shareholders at a public offering price of $10.75 per share. Cision is not selling any ordinary shares in the offering and will not...

at 20:30
Zhaopin Limited ("Zhaopin" or the "Company"), a leading career platform in China focused on connecting users with relevant job opportunities throughout their career lifecycle, found in its 2018 spring survey that about 70% of white-collar workers in...

at 20:18
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it has selected 4,000 liter (L) Custom Single Run...

at 19:59
Proteostasis Therapeutics, Inc. , a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced...

at 19:44
Xencor, Inc. today announced the pricing of an underwritten public offering of 7,300,000 shares of its common stock at a price to the public of $31.00 per share. All of the shares are being sold by Xencor. The gross proceeds to Xencor from the...

News published on 7 december 2017 at 17:03 and distributed by: